Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.
Wistuba II, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher SG, Kalhor N, Moran CA, Gutin A, Lanchbury JS, Barberis M, Kim ES. Wistuba II, et al. Clin Cancer Res. 2013 Nov 15;19(22):6261-71. doi: 10.1158/1078-0432.CCR-13-0596. Epub 2013 Sep 18. Clin Cancer Res. 2013. PMID: 24048333 Free PMC article.
Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.
Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, Beltran L, Greenberg D, Møller H, Reid JE, Gutin A, Lanchbury JS, Brawer M, Scardino P. Cuzick J, et al. Among authors: reid je. Br J Cancer. 2015 Jul 28;113(3):382-9. doi: 10.1038/bjc.2015.223. Epub 2015 Jun 23. Br J Cancer. 2015. PMID: 26103570 Free PMC article.
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Møller H, Scardino P, Warren JD, Park J, Younus A, Flake DD 2nd, Wagner S, Gutin A, Lanchbury JS, Stone S; Transatlantic Prostate Group. Cuzick J, et al. Among authors: reid je. Lancet Oncol. 2011 Mar;12(3):245-55. doi: 10.1016/S1470-2045(10)70295-3. Lancet Oncol. 2011. PMID: 21310658 Free PMC article.
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Telli ML, et al. Among authors: reid j. Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8. Clin Cancer Res. 2016. PMID: 26957554 Free PMC article. Clinical Trial.
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, Perry M, Park J, Younus A, Gutin A, Foster CS, Scardino P, Lanchbury JS, Stone S; Transatlantic Prostate Group. Cuzick J, et al. Among authors: reid je. Br J Cancer. 2012 Mar 13;106(6):1095-9. doi: 10.1038/bjc.2012.39. Epub 2012 Feb 23. Br J Cancer. 2012. PMID: 22361632 Free PMC article.
98 results